 
      INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
Enrollment in the Company’s Phase II study using XProTM to treat patients with Alzheimer’s Disease with neuroinflammation is accelerating in sites outside the US and the Company is maintaining its timeline to successfully conclude the trial. In the US, the …
 
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
  
 
     
     
     
     
     
     
     
     
     
     
     
    